Nuestro blog

The challenges associated with conducting central nervous system clinical research all impact sponsors’ and study teams’ ability to gather stronger therapeutic evidence—but they also prime CNS studies for decentralization.

Many clinical trial sponsors don’t understand how decentralized clinical trials (DCTs) fit within today’s regulatory landscape. This lack of familiarity with decentralized research and regulatory approaches has created DCT hesitancy among sponsors.

Patient engagement in clinical trials can make or break a study. Engaged patients are more likely to participate and complete studies, which can strengthen data collection and, ultimately, provide more robust therapeutic evidence of safety and efficacy.

Clinical trials lay the foundation for breakthrough drugs, digital therapeutics, and medical devices—and, at the center of these studies are the patients.

When it comes to clinical trials, DCT and digital therapeutic (DTx) companies are natural partners. Both are tech savvy and adept in digital health

Decentralized clinical trials offer an effective avenue to mitigate the issues that typify pediatric clinical trials, including patient-reported data accuracy.

Though incidences of pneumonia have decreased overall, the disease is the leading infectious cause of death in children globally, affecting 1 in 6 child deaths.

In our conversations with trial sponsors, ObvioHealth often tackles common misconceptions about decentralized clinical trials (DCTs). These myths hinder our industry’s evolution by keeping sponsors from designing optimal trials that deliver better data with higher retention and compliance rates.